XML Print


Biology Research Center, Faculty of Basic Sciences, Imam Hossein University, Tehran, Iran
Abstract:   (103 Views)
Introduction: Shigellosis is a form of acute intestinal infection and one of the global health problems that occur in human by pathogenic species of Shigella. Producing a cost-effective and protective vaccine against the pathogenic strains of these bacteria will have a significant effect on the improvement of public health. The purpose of this research¬ was to design, express and purify a multiepitope protein as a candidate vaccine against Shigella pathogenic species. Methods: The multi-epitope protein-encoding Ipas, Omps and IcsA genes was designed based on previous bioinformatics assessments and synthesized in pET28a (+) expression vector. Since no detectable expression was observed, the gene was subcloned into pET32a (+). The pET32a (+) recombinant vector containing the desired gene was transferred into Escherichia coli BL21 (DE3) and the expression of the recombinant protein was induced using IPTG. The protein was purified using a nickel column. Finally, the Western blotting method was used to confirm the expression of the recombinant protein. Results: The sub-cloning of the gene was confirmed using PCR reaction. Gene expression analysis showed that the desired protein had a suitable expression. Western blotting analysis confirmed the expression of the recombinant protein. Conclusion: The expressed and purified multi-epitope recombinant protein, containing the main epitopes of the common antigens of pathogenic Shigella species could be achieved as the first step to design a multiepitope vaccine candidate against shigellosis.
Full-Text [PDF 431 kb]   (48 Downloads)    
Type of Study: Original article | Subject: Humanand veterinary vaccines
Received: 2021/08/22 | Accepted: 2021/06/10 | Published: 2021/12/15

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.